Your trusted source for investing success

Tag: NHS

Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting

 –Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016–
–Webcast with APEX Study Executive Committee Members Today at 11 a.m. ET–
MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. , May 27, 2016 (GLOBE NEWSWIRE) — Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) announced that the full results of its pivotal

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
5 Top NASDAQ Biotech Stocks: Kura Takes the Week